Loading
Accent Therapeutics makes tablets aimed at cancers whose cells carry the wrong number of chromosomes, a weakness that healthy cells do not share. Its lead medicine is being tested in ovarian and squamous lung cancer.
Accent Therapeutics, based in Lexington, Massachusetts, develops oral small molecules against dependencies created by genomic and chromosomal instability. Its lead programme ATX-295 is an inhibitor of the mitotic kinesin KIF18A, which the company describes as selectively essential in tumours with high chromosomal instability; it is in a phase 1/2 trial (NCT06799065) in advanced or metastatic solid tumours including high-grade serous ovarian cancer and squamous non-small cell lung cancer, and the company states it keeps full worldwide rights to the programme. A second clinical programme, ATX-559, an oral inhibitor of the RNA helicase DHX9, entered a first-in-human trial in molecularly defined cancers (NCT06625515), which the registry lists as terminated. The company reported FDA Fast Track designation for both ATX-295 and ATX-559 in April 2025, and in October 2025 announced that Boehringer Ingelheim had obtained a preclinical oncology programme from it. Its first registered cancer trial, NCT06625515, was posted on ClinicalTrials.gov in October 2024.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/